A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of PHX1149T as Monotherapy in Subjects with Type 2 Diabetes Mellitus
200 mg
400 mg
Placebo
Paraná, Entre Ríos Province, Argentina
Caba, Buenos Aires, Argentina
La Plata, Buenos Aires, Argentina
Lanús, Buenos Aires, Argentina
Salta, Salta Province, Argentina
Rosario, Santa Fe Province, Argentina
Corrientes, Argentina